Fujifilm Cellular Dynamics, Inc.

Fujifilm Holdings America Corporation

Sarah Burton

Deepika Rajesh

Christie Munn

Maksym A Vodyanyk

Bradley Swanson

Wen Bo Wang

Xin Zhang

Andrew J Brandl

Junying Yu

Jeffrey Sasaki

Anne Strouse

Makiko Ohshima

Katherine Czysz

Ethan McLEOD

Madelyn Donegan

Igor Gurevich

The present disclosure provides methods of producing hepatocytes from induced pluripotent stem cells. Further provided herein are methods of using the hepatocytes for the treatment of a liver disease.

Methods for the production of hepatocytes

Provided herein are methods for the production of antigen-specific effector T cells and NK cells from pluripotent stem cells which express a chimeric antigen receptor (CAR). Further provided herein are methods for the adoptive cell therapy by administering the effector T cells and/or NK cells provided herein.

Antigen-specific immune effector cells

Provided herein are methods for the efficient in vitro differentiation of somatic cell-derived pluripotent stem cells to hematopoietic precursor cells, and the further differentiation of the hematopoietic precursor cells into immune cells of various myeloid or lymphoid lineages, particularly T cells, NK cells, and dendritic cells. The pluripotent cells may be maintained and differentiated under defined conditions; thus, the use of mouse feeder cells or serum is not required in certain embodiments for the differentiation of the hematopoietic precursor cells.

Methods for directed differentiation of pluripotent stem cells to immune cells

Provided herein are methods for the efficient in vitro maintenance, expansion, culture, and/or differentiation of pluripotent cells with disruption of the MeCP2 gene into various erythroid, myeloid, lymphoid, or endoderm lineages, particularly mature erythrocytes. The pluripotent cells may be maintained and differentiated under defined conditions; thus, the use of mouse feeder cells or serum is not required in certain embodiments for the differentiation of the precursor cells.

Generating mature lineages from induced pluripotent stem cells with MECP2 disruption

The present disclosure generally regards methods and compositions for providing multi-lineage hematopoietic precursor cells from pluripotent stem cells (PSCs). The PSCs comprise an expression construct encoding an ETS/ERG gene, GATA2 and HOXA9. Also provided are methods for providing hematopoietic stem cells capable of long-term engraftment in mammals, such as humans. Further provided are therapeutic compositions including the provided hematopoietic stem cells and precursors of hematopoietic cells, and methods of using such for the treatment of subjects.

Multi-lineage hematopoietic precursor cell production by genetic programming

Provided herein are methods for the in vitro differentiation of induced pluripotent stem cells, which have been expanded and/or maintained under defined conditions, into endodermal precursor cells (EPCs) that are capable of producing mono-hormonal beta cells.

Methods and compositions for culturing endoderm progenitor cells in suspension

Growing community of inventors

Madison, WI, United States of America

Sarah Burton